Antiarrhythmic Medication Management
General Principles
- The European Society of Cardiology recommends that antiarrhythmic drugs should be selected based primarily on safety considerations rather than efficacy, with treatment tailored to the specific arrhythmia type and underlying cardiac condition 1
- Antiarrhythmic drugs are classified according to the Vaughan Williams schema (classes I-IV) or the more mechanistic Sicilian Gambit system 2
- Administration route for life-threatening arrhythmias should be intravenous, with a 20 ml saline bolus following peripheral administration to aid delivery to central circulation 3, 4
- Before initiating antiarrhythmic therapy, reversible precipitants of arrhythmias should be identified and corrected (e.g., coronary disease, valvular disease, hypertension, heart failure) 5
Management of Ventricular Arrhythmias
- For unstable VT with adverse signs, immediate synchronized DC cardioversion is recommended 4, 6
- For stable VT, lidocaine is first-line therapy: 50 mg IV over 2 min, repeated every 5 min to total dose of 200 mg, followed by infusion at 2 mg/min 3, 4, 6
- Amiodarone is second-line for VT refractory to lidocaine: 5 mg/kg over one hour, followed by 15 mg/kg over 24 hours 4, 6
- Early defibrillation is the primary treatment for ventricular fibrillation; pharmacological therapy is secondary 3
- For refractory VF, use drugs outlined for VT 3
- Magnesium may be effective for refractory VF, particularly when associated with acute myocardial infarction: 8 mmol bolus followed by 2.5 mmol/h infusion 3, 4
Management of Supraventricular Arrhythmias
- For patients with lone AF, first-line treatment includes beta-blockers, flecainide, propafenone, or sotalol 5, 7
- For patients with structural heart disease or heart failure, amiodarone and dofetilide are first-line options 1, 5, 7
- Class IC drugs (flecainide, propafenone) are contraindicated in patients with structural heart disease due to risk of life-threatening ventricular arrhythmias 1
- For vagally-induced AF, long-acting disopyramide is preferred due to its anticholinergic activity 5, 7
- For adrenergically-mediated AF, beta-blockers are first-line treatment 5, 7
Long-Term Management Considerations
- Antiarrhythmic drug therapy approximately doubles sinus rhythm maintenance compared to no therapy 1
- Beta-blockers are the only antiarrhythmic agents shown to reduce sudden arrhythmic death, especially in patients with prior myocardial infarction or heart failure 8
- When one antiarrhythmic drug fails, a clinically acceptable response may be achieved with another agent 1
- For difficult cases, drug combinations may be effective (e.g., beta-blocker, sotalol, or amiodarone with a class IC agent) 5, 7
Monitoring and Safety Considerations
- Proarrhythmia (drug-induced arrhythmias) is a significant risk with antiarrhythmic drugs 1
- Serum potassium levels should be in the normal range before cardioversion 5
- Specific monitoring requirements include: